Association of antibiotics with the outcomes in COVID-19 pneumonia patients with elevated PCT levels

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2024-06-08 DOI:10.1016/j.rmed.2024.107697
Lekhya Raavi , Shahin Isha , Sadhana Jonna , Emily C. Craver , Hrishikesh Nataraja , Anna Jenkins , Abby J. Hanson , Arvind Bala Venkataraman , Prasanth Balasubramanian , Aysun Tekin , Vikas Bansal , Sean M. Caples , Syed Anjum Khan , Nitesh K. Jain , Abigail T. LaNou , Rahul Kashyap , Rodrigo Cartin-Ceba , Bhavesh M. Patel , Ricardo Diaz Milian , Carla P. Venegas , Devang K. Sanghavi
{"title":"Association of antibiotics with the outcomes in COVID-19 pneumonia patients with elevated PCT levels","authors":"Lekhya Raavi ,&nbsp;Shahin Isha ,&nbsp;Sadhana Jonna ,&nbsp;Emily C. Craver ,&nbsp;Hrishikesh Nataraja ,&nbsp;Anna Jenkins ,&nbsp;Abby J. Hanson ,&nbsp;Arvind Bala Venkataraman ,&nbsp;Prasanth Balasubramanian ,&nbsp;Aysun Tekin ,&nbsp;Vikas Bansal ,&nbsp;Sean M. Caples ,&nbsp;Syed Anjum Khan ,&nbsp;Nitesh K. Jain ,&nbsp;Abigail T. LaNou ,&nbsp;Rahul Kashyap ,&nbsp;Rodrigo Cartin-Ceba ,&nbsp;Bhavesh M. Patel ,&nbsp;Ricardo Diaz Milian ,&nbsp;Carla P. Venegas ,&nbsp;Devang K. Sanghavi","doi":"10.1016/j.rmed.2024.107697","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To assess antibiotics impact on outcomes in COVID-19 pneumonia patients with varying procalcitonin (PCT) levels.</p></div><div><h3>Methods</h3><p>This retrospective cohort study included 3665 COVID-19 pneumonia patients hospitalized at five Mayo Clinic sites (March 2020 to June 2022). PCT levels were measured at admission. Patients’ antibiotics use and outcomes were collected via the Society of Critical Care Medicine (SCCM) Viral Infection and Respiratory Illness Universal Study (VIRUS) registry. Patients were stratified into high and low PCT groups based on the first available PCT result. The distinction between high and low PCT was demarcated at both 0.25 ng/ml and 0.50 ng/ml.</p></div><div><h3>Results</h3><p>Our cohort consisted of 3665 patients admitted with COVID-19 pneumonia. The population was predominantly male, Caucasian and non-Hispanic. With the PCT cut-off of 0.25 ng/ml, 2375 (64.8 %) patients had a PCT level &lt;0.25 ng/mL, and 1290 (35.2 %) had PCT ≥0.25 ng/ml. While when the PCT cut off of 0.50 ng/ml was used we observed 2934 (80.05 %) patients with a PCT &lt;0.50 ng/ml while 731(19.94 %) patients had a PCT ≥0.50 ng/ml. Patients with higher PCT levels exhibited significantly higher rates of bacterial infections (0.25 ng/ml cut-off: 4.2 % vs 7.9 %; 0.50 ng/ml cut-off: 4.6 % vs 9.2 %).</p><p>Antibiotics were used in 66.0 % of the cohort. Regardless of the PCT cutoffs, the antibiotics group showed increased hospital length of stay (LOS), intensive care unit (ICU) admission rate, and mortality. However, early de-escalation (&lt;24 h) of antibiotics correlated with reduced hospital LOS, ICU LOS, and mortality. These results were consistent even after adjusting for confounders.</p></div><div><h3>Conclusion</h3><p>Our study shows a substantial number of COVID-19 pneumonia patients received antibiotics despite a low incidence of bacterial infections. Therefore, antibiotics use in COVID pneumonia patients with PCT &lt;0.5 in the absence of clinical evidence of bacterial infection has no beneficial effect.</p></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124001719","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To assess antibiotics impact on outcomes in COVID-19 pneumonia patients with varying procalcitonin (PCT) levels.

Methods

This retrospective cohort study included 3665 COVID-19 pneumonia patients hospitalized at five Mayo Clinic sites (March 2020 to June 2022). PCT levels were measured at admission. Patients’ antibiotics use and outcomes were collected via the Society of Critical Care Medicine (SCCM) Viral Infection and Respiratory Illness Universal Study (VIRUS) registry. Patients were stratified into high and low PCT groups based on the first available PCT result. The distinction between high and low PCT was demarcated at both 0.25 ng/ml and 0.50 ng/ml.

Results

Our cohort consisted of 3665 patients admitted with COVID-19 pneumonia. The population was predominantly male, Caucasian and non-Hispanic. With the PCT cut-off of 0.25 ng/ml, 2375 (64.8 %) patients had a PCT level <0.25 ng/mL, and 1290 (35.2 %) had PCT ≥0.25 ng/ml. While when the PCT cut off of 0.50 ng/ml was used we observed 2934 (80.05 %) patients with a PCT <0.50 ng/ml while 731(19.94 %) patients had a PCT ≥0.50 ng/ml. Patients with higher PCT levels exhibited significantly higher rates of bacterial infections (0.25 ng/ml cut-off: 4.2 % vs 7.9 %; 0.50 ng/ml cut-off: 4.6 % vs 9.2 %).

Antibiotics were used in 66.0 % of the cohort. Regardless of the PCT cutoffs, the antibiotics group showed increased hospital length of stay (LOS), intensive care unit (ICU) admission rate, and mortality. However, early de-escalation (<24 h) of antibiotics correlated with reduced hospital LOS, ICU LOS, and mortality. These results were consistent even after adjusting for confounders.

Conclusion

Our study shows a substantial number of COVID-19 pneumonia patients received antibiotics despite a low incidence of bacterial infections. Therefore, antibiotics use in COVID pneumonia patients with PCT <0.5 in the absence of clinical evidence of bacterial infection has no beneficial effect.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗生素与 PCT 水平升高的 COVID-19 肺炎患者预后的关系。
目的评估抗生素对不同降钙素原(PCT)水平的 COVID-19 肺炎患者预后的影响:这项回顾性队列研究纳入了在梅奥诊所五家医院住院的 3,665 名 COVID-19 肺炎患者(2020 年 3 月至 2022 年 6 月)。入院时测定 PCT 水平。患者的抗生素使用情况和结果通过重症医学学会(SCCM)病毒感染和呼吸道疾病普遍研究(VIRUS)登记处收集。根据首次获得的 PCT 结果将患者分为高 PCT 组和低 PCT 组。高PCT和低PCT的区分以0.25纳克/毫升和0.50纳克/毫升为界:我们的队列由 3,665 名 COVID-19 肺炎患者组成。患者主要为男性、白种人和非西班牙裔人。以 PCT 0.25 纳克/毫升为临界值,有 2375 名(64.8%)患者的 PCT 水平达到了结论水平:我们的研究表明,尽管细菌感染发生率较低,但仍有大量 COVID-19 肺炎患者接受了抗生素治疗。因此,在没有细菌感染临床证据的情况下,对 PCT < 0.5 的 COVID 肺炎患者使用抗生素并无益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
期刊最新文献
Understanding the acceptability of the changing model of care in cystic fibrosis Efficacy of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary disease and exercise pulmonary hypertension Epistaxis in COVID positive ICU patients, implications, and future interventions Prognostic Role of Pleural Fluid SUVpeak Value obtained from 18F-FDG PET/CT in patients with Malignant Pleural Effusion. β-Blockers and Asthma: Surprising findings from the FAERS database
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1